These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28231559)

  • 1. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.
    Ciccarese C; Massari F; Iacovelli R; Fiorentino M; Montironi R; Di Nunno V; Giunchi F; Brunelli M; Tortora G
    Cancer Treat Rev; 2017 Mar; 54():68-73. PubMed ID: 28231559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular underpinnings of prostate cancer: impacts on management and pathology practice.
    Rodrigues DN; Boysen G; Sumanasuriya S; Seed G; Marzo AM; de Bono J
    J Pathol; 2017 Jan; 241(2):173-182. PubMed ID: 27753448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
    Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
    Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
    Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
    Liu L; Dong X
    PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERα.
    Talesa VN; Ferri I; Bellezza G; Love HD; Sidoni A; Antognelli C
    Prostate; 2017 Feb; 77(2):196-210. PubMed ID: 27696457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Akt-regulated pathways in prostate cancer.
    Majumder PK; Sellers WR
    Oncogene; 2005 Nov; 24(50):7465-74. PubMed ID: 16288293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
    Edlind MP; Hsieh AC
    Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways.
    Tortorella E; Giantulli S; Sciarra A; Silvestri I
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of lncRNAs in prostate cancer development and progression.
    Weiss M; Plass C; Gerhauser C
    Biol Chem; 2014 Nov; 395(11):1275-90. PubMed ID: 25153594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
    Sarker D; Reid AH; Yap TA; de Bono JS
    Clin Cancer Res; 2009 Aug; 15(15):4799-805. PubMed ID: 19638457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
    Sircar K; Yoshimoto M; Monzon FA; Koumakpayi IH; Katz RL; Khanna A; Alvarez K; Chen G; Darnel AD; Aprikian AG; Saad F; Bismar TA; Squire JA
    J Pathol; 2009 Aug; 218(4):505-13. PubMed ID: 19402094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of mTOR signaling pathway proteins and proteins influencing mTOR pathway in resistance to radiotherapy in prostate cancer.
    Benderli Cihan Y
    J BUON; 2018; 23(6):1931-1932. PubMed ID: 30610829
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular foundations for personalized therapy in prostate cancer.
    Fisher KW; Montironi R; Lopez Beltran A; Moch H; Wang L; Scarpelli M; Williamson SR; Koch MO; Cheng L
    Curr Drug Targets; 2015; 16(2):103-14. PubMed ID: 25547910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies.
    Xi Y; Chen Y
    J Cell Biochem; 2015 Sep; 116(9):1837-47. PubMed ID: 25773992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
    Frank S; Nelson P; Vasioukhin V
    F1000Res; 2018; 7():. PubMed ID: 30135717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
    Bitting RL; Armstrong AJ
    Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.